INTRODUCTION
Cytokines had originally been thought to be glycoproteins functioning largely in hematolymphopoiesis and immune reaction. In the 1990s, there have been an increasing number of reports showing that cytokines also play important roles in other organs and tissues, including the nervous system. Now the concepts of the nervous system as an immunologically privileged site have been significantly modified (62) . Most cytokines are produced and have several functions in the nervous system (24, 63) . Among these several functions, many neuroscientists have focused on the trophic or protective (48) , and inversely toxic (62, 73) , influences on neurons. Lack of such cytokines or excesses have been thought to be important with respect not only to etiologies and pathogenesis but also to developing therapies for several neurologic disorders (45, 62, 77) . In fact, cytokines have been reported to be involved in the etiopathogenesis of several neurologic disorders (14, 32, 45, 53, 59, 63, 78) , suggesting that analyses of cytokine functions in the nervous system are important: 1) to clarify the precise mechanisms deciding the direction in bidirectional effects (trophic and toxic) of cytokines on neurons; and 2) to modify the pathologies of neurologic diseases and delay their progression. However, clinical trials based on such a hypothesis have been restricted to a few neurologic disorders, for example, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), using a very limited number of cytokines such as ciliary neurotrophic factor (CNTF), insulin-like growth factor I (IGFI), and interferons (IFNs) (19, 77) . In addition, the pharmacology, pharmacokinetics, and ad-verse effects of most cytokines in the nervous system, have not yet been clarified. Information on pharmacological characteristics is very limited. Compared with studies of other cytokines, the effects of interleukin-1 (IL-1) and its related molecules, administered to the central nervous system (CNS) and peritoneal cavity on ischemic lesions and their mechanisms have long been extensive and detailed (62, 63) . In addition, there is some information concerning the pharmacology of IL-2 (21), IL-3, IL-6 (16), leukemia-inhibitory factor (LIF) (52) , , granulocyte-macrophage colony-stimulating factor (GM-CSF) (34) , macrophage CSF (M-CSF) (2) , erythropoietin (34, 64) , IFNs (19, 68) , tumor necrosis factor α (TNFα) (25, 59) , and members of the transforming growth factor β (TGFβ) superfamily, including glial cell line-derived neurotrophic factor (GDNF) (14, (38) (39) (40) 47) , which were administered to the nervous systems of study animals. Therefore, the future prospects of cytokines in therapeutic strategies to modulate the pathological course of neurologic diseases can be considered. Furthermore, transgenic mice overexpressing cytokines (4, 78) and mutants, such as M-CSF null mutant osteopetrotic (op/op) mice (2, 50) , stem cell factor (SCF) mutant (Sl ) mice, and c-kit CSF receptor mutant (W ) mice (23) , will also provide useful information on the in vivo effects of cytokines on the nervous system. This review on the neurotrophic actions of IL-3 should generate interest in every cytokine as a possible candidate for therapeutic strategies against neurologic disorders and provide detailed information regarding the function of IL-3 in the nervous system. The lack of cytokines or their excesses are not involved in the primary etiologies of neurologic disorders, but they are responsible for subsequent pathological changes. Numerous results from analyses of the actions of cytokines on the nervous system and from studies of transgenic and knockout mice, although emphasized repeatedly, will be helpful in discovering the mechanisms involved in the bidirectional (trophic and cytotoxic) effects of cytokines on neurons and in developing strategies to delay the progression of neurologic disorders.
OVERVIEW

Chemistry of IL-3
IL-3 is a relatively small protein, with a polypeptide chain of 140 amino acid residues in the mouse and 133 in the human, and it is heavily glycosylated (65) . Whereas the synthesized polypeptide has a molecular weight of 14,000, IL-3 released from a natural source has a molecular weight of 20,000-40,000 (65) . This variation in molecular weight is due to differences in glycosylation (65) .
Pharmacology of IL-3
IL-3 is also known as a multicolony-stimulating factor, which mainly stimulates the generation and differentiation of hematoprogenitors of every lineage derived from pluripotential hematopoietic stem cells (65) . IL-3 is produced from immunologically activated T lymphocytes (65) , suggesting that IL-3 is not involved in steady-state or constitutive hematopoiesis but in inductive hematopoiesis on exposure to immunological stress (65 transcription of IL-3 is enhanced by a protein kinase C activator, phorbol myristate acetate, and calcium ionophore A23187 (75) . IL-3 exerts its effects via a specific high-affinity cell surface receptor (27) . The high-affinity IL-3 receptor (IL-3R) is composed of two subunits, an IL-3-specific α subunit (IL-3Rα), which is a primary ligand binding protein, and a β subunit (IL-3Rβ), which is primarily responsible for signaling (22, 27, 33) . Mice have two β subunits for IL-3R, an IL-3-specific β subunit (IL-3RβIL-3) and a common β subunit (IL-3Rβ c ) shared by IL-3, GM-CSF, and IL-5 receptors (22) . In contrast to mice, humans have only IL-3Rβ c (33) . Neither subunit contains intrinsic kinase activity in its cytoplasmic domain (22, 27, 33) . The binding of IL-3 to its receptor results in tyrosine phosphorylation of IL-3Rβ followed by a number of other cellular events, such as tyrosine phosphorylation of Jak kinases and Stats (27) .
Overview of Reports Concerning IL-3 in the Nervous System
For convenience, the history of IL-3 research in the nervous system is reviewed here ( Table 1) . The report by Frei et al. (15) is one of the first in elucidating IL-3 function in the brain. This report showed that an IL-3-like factor is produced from mouse astrocytes after exposure to lipopolysaccharide (LPS). As Malipiero et al. (42) and Ohno et al. (55) demonstrated later, this IL-3-like factor was shown to be GM-CSF. As a result of the work conducted by Frei et al. (15) , the study of cytokines other than IL-1 began to flourish in (Table 2 ).
IL-3 and the Peripheral Nervous System
Moroni and Rossi (51) reported that the decrease in the number of cultured sensory neurons treated with IL-3 is less than that seen without treatment. The sensory neurons were prepared from the dorsal root ganglia of Day 8 chick embryos and then cultured for 4 d. IL-3 and other factors were added at the beginning of the cultures. Over a 4-d period of observation, the rate of decrease in control and IL-3-treated cells differed significantly. Furthermore, even if IL-3 was withdrawn after 2 d of culture, the survival effect of IL-3 persisted at least 2 more days. They also showed that IL-3 promotes the network formed by well-developed neurons positive for neurofilament protein. The mechanisms involved in the in vitro IL-3 effects on survival and differentiation of sensory neurons remain unclear.
A study in perspectives on neural-immune interactions was conducted by Kannan et al. (30) , although this study focused on the neurite-promoting activity of endogenous cytokines produced from lymphoid tissues such as thymus, spleen, and mesenteric lymph nodes. They performed cocultures of the explants of superior cervical ganglia (SCG) and mesenteric lymph node (MLN) and observed the increase in neurite outgrowth from SCG CNS Drug Reviews, Vol. 5 Abbreviations: IL-3, interleukin-3; IL-3Rβ c , interleukin-3 receptor common β subunit; CNS, central nervous system; GM-CSF, granulocyte-macrophage colony-stimulating factor.
toward MLN. Interestingly, the neurite outgrowth toward MLN that was explanted from mice transfected by Nippostrongylus brasiliensis is blocked by addition of an anti-IL-3 antibody, as well as anti-IL-1β and anti-nerve growth factor (NGF) antibodies, suggesting that the enhancement of neurite outgrowth of SCG is partly induced by IL-3 released from MLN with infection. They furthermore demonstrated that this action of IL-3 on SCG neurons to promote neurite outgrowth is directly induced via IL-3R followed by mitogenactivated protein (MAP) kinase pathway, using cultured sympathetic neurons from mouse SCG with in vitro treatment of IL-3 (Kannan Y, Moriyama M, Sugano T, et al., Neurotrophic action of interleukin-3 on mouse sympathetic neurons, submitted for publication).
IL-3 AND THE CENTRAL NERVOUS SYSTEM Specific in Vitro Effects of IL-3 on Cholinergic Neurons and Their Mechanisms
Kamegai et al. (29) reported that IL-3 augments the activity of the acetylcholine (ACh)-synthesizing enzyme, choline acetyltransferase (ChAT), in cholinergic neurons cultured from the septal area of embryonic mouse forebrain. This in vitro effect of IL-3 is dose dependent (maximum at 50 Units/ml) and maximal 5 d after the initiation of culture. As IL-3 affects neither the protein content nor the cell number of cholinergic neurons (72), IL-3 is thought to enhance biochemical differentiation. The addition of anti-IL-3 and anti-IL-3R antibodies to the cultures blocks the effect of exogenous IL-3 on ChAT activity; however, the addition of an anti-NGF receptor or anti-insulin-like growth factor II (IGFII) receptor antibody has no influence on this IL-3 effect (72). IL-3 also increases ChAT activity in cholinergic cell line SN6 (20, 29, 72) . IL-3R α and β subunits are found in cholinergic neurons in cultures and also in sections from the basal forebrain of mice and rats (35, 71, 72) . These findings strongly suggest that such in vitro IL-3 effects are directly mediated via IL-3R expression in cholinergic neurons. NGF and IGFII are reported to increase ChAT activity (37, 41) , but this IL-3 action is not due to induction of NGF release followed by its binding to NGF receptors (NGFR). In fact, the increases in NGF concentrations in both cell lysates and conditioned media are not observed in cholinergic neurons cultured in the presence of IL-3 (34). The IGFII receptor (IGFIIR) is identical to the cation-independent mannose-6-phosphate receptor (CI/MPR) (17) . CI/MPR is expected to recognize sugar chains bound to cytokine molecules such as TGF β (17) . But this IL-3 effect is not mediated by the binding of sugar chains of IL-3 to IGFIIR, as demonstrated in the result obtained using the anti-IGFIIR antibody (72) .
IL-3 is shown to increase expression of IL-3R mRNA, especially the β subunit mRNA in cholinergic cell line SN6 (35, 71) . SN6 expresses IL-3R mRNA for both α and β subunits, but another cholinergic cell line, SN49, expresses only α subunit mRNA (35) . The increase in ChAT activity in SN49 is not observed with treatment of IL-3 (35) , but the increase in SN6 is seen as mentioned above. The action of IL-3 on ChAT activity is thought to require the β subunit, although it is not certain whether the α subunit is also necessary. Signal transduction downstream from IL-3R in cholinergic neurons has not been clarified at all. IL-3 also increases expression of ChAT mRNA in SN6 cells, but the increase is very slight (35, 71) . The increase in promoter activity in the 5′-noncoding region of the ChAT gene measured by reporter gene assay using luciferase is significantly induced but very slight in SN6 cells treated with IL-3 (35) . Therefore, these facts may suggest that the increase in ChAT activity by IL-3 treatment is partially regulated by mechanisms other than transcription factors. However, ChAT possesses an extremely high specific activity as an enzyme that synthesizes ACh from choline and acetyl coenzyme A (58), indicating that the relatively slight increases in ChAT mRNA and promoter activity are adequate to furthermore synthesize functional amounts of ACh by IL-3 treatment.
Interestingly, the intracellular ACh content in cholinergic neurons treated with IL-3 for 2 to 3 d is decreased more than 50% compared with that without IL-3 treatment (35, 72 ). This decrease is followed by an increase in the intracellular ACh content with IL-3 treatment for 5 more days (35) . IL-3 hardly influences the activity of acetylcholinesterase (AChE) (35) , which hydrolyzes ACh to choline and acetic acid. In fact, IL-3 has been found to increase ACh release from SN6 cells (Konishi Y, Harano T, Fujii T, et al. IL-3-induced events in a septum-derived cholinergic cell line, manuscript in preparation). ACh synthesized by ChAT in the cytoplasm of cholinergic neurons is packaged in the synaptic vesicles of cholinergic neurons by mechanisms involving vesicular ACh transporter (VAChT) (74) . The increase in VAChT mRNA is also observed in SN6 cells treated with IL-3 (35, 71) . The effect of IL-3 on choline uptake has not been examined as yet. Kamegai et al. (29) also reported the in vivo effect of IL-3 on cholinergic neurons. Intraventricularly infused IL-3 promotes neuronal survival of cholinergic neurons in the medial septal area of rats subjected to fimbria-fornix transection. This transection results in disconnection of cholinergic projecting fibers from the medial septum to the hippocampus. The transection was performed unilaterally, and then IL-3 was infused to the contralateral ventricle. The pathway and mechanism of infused IL-3 leading to the promotion of neuronal survival have not been clarified. Moreover, it is interesting to note that one shot infusion is better than continuous infusion. IL-3 loses more than 50% of its biological activity in vitro by incubation for 1 d at 37°C (Kamegai M, unpublished) . Expression of the IL-3R α subunit was examined in the medial septal area in rats subjected to the fimbria-fornix transection but without IL-3 treatment. IL-3R α subunit-positive neurons in this area tend to be preserved, compared with the ChAT-positive neurons (71) . As observed by D. H. Chui (unpublished), the number of IL-3R α subunit-positive neurons is almost similar to that of IL-3R β subunit-positive ones that account for 40% (72) of ChAT-positive neurons in the medial septal area of nontreated rats. Therefore, approximately 40% of ChAT-positive neurons in the medial septal nuclei express the IL-3R α subunit as well, although a small number of noncholinergic neurons in other area, such as the hippocampus and cerebral cortex, express IL-3R α and β subunits (71, 72 (44) mentioned that IL-3 is one of the cholinergic differentiation factors produced from microglia. They showed that addition of microglia to septal neuronal cultures (cocultures) enhances ChAT activity in the septal neurons and that an anti-IL-3 antibody suppresses this enhancement effect. They also showed that IL-3 is detected in both conditioned media and cell homogenates from cocultures of the septal neurons and microglia. Jonakait et al. (28) 
Specific in Vivo Effects of IL-3 on Cholinergic Neurons and Their Mechanisms
In Vitro Effects of IL-3 on Other Types of Neurons and Their Mechanisms
IL-3 actions on neurons in the CNS are not restricted to cholinergic neurons in the basal forebrain. Kamegai et al. (29) found that IL-3 can also affect γ-aminobutyric acid (GABAergic) neurons in primary septal neuronal cultures by slightly but significantly elevating glutamic acid decarboxylase (GAD) activity. A similar effect on GAD activity was reported by Mazzoni and Kenigsberg (44). Tabira et al. (72) examined the in vitro effects of IL-3 on several amino acids and monoamines by using an amino acid analyzer and highpressure liquid chromatography with electrochemical detection. Among several neurotransmitters, IL-3 seems to influence GABAergic as well as cholinergic systems (72) . The precise localization of IL-3R in the brain has not been examined as yet with the exception of the basal forebrain, cerebral cortex, and hippocampus (71, 72, 76) .
In addition to the cholinergic cell line, SN6, and other SN lines immortalized from the septal area of mice by using somatic cell fusion techniques (20) , the in vitro actions of IL-3 have been examined in two other nervous system-derived noncholinergic cell lines immortalized by transduction of simian virus 40 (SV40) large T-antigen. One is the S1 cell line, which was established from the diencephalon of embryonic rats by Shimoda et al. (66) and is thought to be a neuronal cell line. S1 cells extend cell processes showing neuronal morphology on exposure to IL-3 (66). They showed that this effect is mediated via signal transduction pathways involving jak2 and stat6 (67) . The other is the ST14A cell line, which was established from the striatum primordia of embryonic mice and is thought to be a progenitor line positive for nestin. They showed that ST14A cells stably transfected by DNA encoding α and β subunits of IL-3R proliferate upon exposure to IL-3 and that this response is mediated via functional reconstitution of IL-3R followed by phosphorylation of jak2 and stat5 (5). These reports provide useful information to seek molecules involved in IL-3-induced signal transduction pathways in cholinergic neurons.
In Vivo Effects of IL-3 on Other Types of Neurons and Their Mechanisms
Recently, Wen et al. (76) produced a report highlighting the in vivo effect of IL-3 on noncholinergic systems in the brain. According to their report, 7-d IL-3 infusion into the lateral ventricles of gerbils subjected to transient forebrain ischemia prevents hippocampal CA1 neuron death and ischemia-induced learning disability. They demonstrated that the protective effects of IL-3 are mediated by ischemia-induced upregulation of IL-3Rα subunit protein in hippocampal CA1 neurons. Especially ischemia enhances the IL-3Rα expression in the CA1 field, not in the CA3 field. In addition, ischemia induces the upregulation of Bcl-xL mRNA as well as the IL-3Rα subunit protein, but decreases Bcl-xL protein expression in the hippocampal CA1 neurons. They showed that IL-3 infusion prevents the decrease in Bcl-xL protein expression in this area after ischemia, although this has no effect on IL-3Rα subunit levels. Bcl-xL is an apoptosis-inhibiting agent of the Bcl-2 family and is expressed mainly in the brain (76) . In the study by Wen et al. (76) , recombinant IL-3 was continuously infused into the lateral ventricles of gerbils subjected to 3-min forebrain ischemia, although Kamegai et al. (29) recommended that one-shot infusion of IL-3 leads to better protective effects for neurons when compared with continuous IL-3 infusion. Furthermore, Wen et al. subsequently confirmed this effect of IL-3 in vitro, showing that IL-3 induces the expression of Bcl-xL mRNA and protein in primary hippocampal and cortical neurons expressing the IL-3Rα subunit and attenuates neuronal damage caused by a free radical-producing agent, FeSO 4 (76) . In two in vivo studies by Tabira et al. (71) and Wen et al. (76) , ischemia and axotomy seem to induce IL-3Rα subunit expression even if exogenous IL-3 is not administered. These facts may indicate that certain populations of neurons under some stress are primed to react with IL-3 by full expression of the IL-3Rα subunit to maintain cell viability or rescue themselves. Upregulation of IL-3Rα subunit by ischemia, and not by IL-3 treatment, might suggest the existence of endogenous IL-3 production in the brain. This is observed in the in vitro study by Tabira et al. (71) as well, showing that the expression of IL-3Rα subunit in neurons is already maximal and is not upregulated by IL-3 treatment. IL-3Rβ subunit is upregulated in its neuronal expression by IL-3 treatment to cholinergic neuronal cultures (35, 71) . The role of IL-3Rβ subunit in vivo should be examined. The possibility that IL-3Rβ expression is more important than IL-3Rα expression in regulating the response of neurons to IL-3 cannot be excluded. 
CNS
TRANSGENIC AND KNOCKOUT MICE AND THE IL-3/IL-3R SYSTEM
Pharmacokinetics, Toxicology, and Clinical Application
Currently, two laboratories have reported studies using IL-3 overexpression transgenic mice with a focus on the nervous system. Chiang et al. (7) developed transgenic mice in which low levels of IL-3 overexpression were targeted to astrocytes using fusion gene constructs under the control of the glial fibrillary acidic protein (GFAP) promoter. The IL-3-GFAP transgenic mice displayed abnormal motor features, depending on the dose of transgene-encoded IL-3 overexpression. The overexpression of IL-3 at high levels in the CNS resulted in lethal early-onset acute neuroinflammatory disease, while CNS overexpression of IL-3 at low levels was associated with development of late-onset chronic progressive demyelination with remyelination. This chronic CNS production of low levels of IL-3 seems to promote recruitment, proliferation, and activation of macrophages/microglial cells in the white matter of the cerebellum and brainstem with consequent primary demyelination and remyelination. In fact, the expression of IL-3 is particularly prominent in the white matter tracts of the cerebellum and brainstem of the transgenic mice. The findings in this transgenic line indicate that persistent CNS production of low levels of IL-3 promotes pathology and lesions similar to those observed in humans suffering from MS. In addition to the IL-3-GFAP transgenic mice, IL-6-, IFNα-, TNFα-, and IL-12-GFAP transgenic mice have been established and characterized (4, 56) . Interestingly, Paradisis et al. (57) demonstrated that the increase in expression of the receptors for C5a, a potent inflammatory and chemotactic factor, is observed not only in infiltrating macrophages/microglia in the cerebellum but also in neurons in the cerebral cortex and hippocampus of the IL-3-GFAP transgenic mice. These findings suggest that IL-3 may directly regulate C5a receptors (C5aR) in neurons, whereas the function of C5aR in neurons remains unclear. The only known function associated with the C5aR in neurons to date is C5a-mediated α-adrenergic activity in cholinergic neurons in the hypothalamus (57) . Neurons, when bound to C5a upon exposure to IL-3, may possibly result in functional changes in cholinergic neurons accompanied by inflammation.
Chavany et al. (6) generated transgenic mice with widespread overexpression of IL-3 in various organs. This transgenic line exhibited neurologically abnormal motor disturbances and revealed multifocal neuronal degeneration, characterized by vacuolation of neuronal cytoplasm in the brainstem and spinal cord. The neuronal degeneration and loss are seen in motor neurons of the spinal cord that are originally positive for ChAT, microtubule-associated protein (MAP)-2, and neurofilament protein. The motor neurons show loss of immunoreactivity for MAP-2 and neurofilament protein, indicating dendritic loss and axonal degeneration, respectively. A marked loss of neuronal dendrites is also seen in the hippocampus. However, there is no obvious demyelination or microglial infiltration, despite marked astrogliosis. The levels of IL-3 expression in the spinal cord, at both RNA and protein levels, are quite similar to the levels observed in other regions of the CNS than the spinal cord of transgenic mice. They suggested that the pathology in this transgenic line is not triggered directly by the high levels of IL-3 expression but is due to autoimmune reaction targeted mainly to motor neurons in the spinal cord and that it is similar to that observed in ALS and progressive muscular atrophy in humans. The two transgenic models reported by Chiang et al. (7) and Chavany et al. (6) will provide useful information about how IL-3 overexpression can affect neural functions and the difference in the effects of general and localized overexpression of IL-3.
Furthermore, it is interesting to note that downregulation of IL-3 expression by generating a transgenic mouse line expressing anti-IL-3 transgene induces a similar neurologic syndrome and histopathology as seen in the IL-3-GFAP transgenic mice. Cockayne et al. (8) generated a transgenic mouse line that expressed antisense IL-3 RNA under the control of T cell B19 promoter, so that the expression was limited to hematopoietic cells. The antisense IL-3 (AS-IL-3) transgenic mice exhibited either of two independently occurring fetal syndromes; a pre-B cell lymphoproliferation or neurologic dysfunction. The neuropathology of the AS-IL-3 showing the latter neurologic dysfunction demonstrates accumulation of reactive astrocytes in the cerebellum, brainstem, and spinal cord, accompanied by activated microglia and a slight loss of neurons in the cerebellar nuclei and motoneurons in the brain stem and spinal cord. The AS-IL-3 transgene is expressed in both the CNS and hematopoietic tissues accompanied by a 95% decrease in IL-3 levels in the periphery (69, 78) . However, interestingly, IL-3 mRNA expression and IL-3 protein levels are increased in astrocytes of the AS-IL-3 brain, in response to the deletion in the periphery (69, 78) . This fact indicates that the regulatory mechanisms related to IL-3 production are different and reciprocal between the CNS and lymphohematopoietic system.
Most recently, D'Andrea et al. (9) reported a study of transgenic mice expressing an activated form of human common β subunit of IL-3 receptors (hβ c FI∆) linked to a promoter fragment from the housekeeping PKG-1 gene. PKG is a housekeeping enzyme expressed in virtually all cell types (9) . These transgenic mice developed not only a myeloproliferative disorder but also a progressive neurologic disorder characterized by symmetrical, bilateral foci of necrosis in the white matter of the brainstem that are different from those observed in the IL-3-GFAP transgenic mice (7) because of no evidence of primary demyelination in the hβ c FI∆ transgenic mice (9) . Expression of the hβ c FI∆ transgene is prominent in the myeloid lineage of bone marrow cells, suggesting that the activated macrophages existing largely in the brainstem can initiate such brain lesions.
Nishinakamura et al. (54) and Kim et al. (31) developed knockout mice deficient for both IL-3 and IL-3Rβ c and transgenic mice expressing human IL-3 and GM-CSF, respectively. This knockout mouse line lacks the entire function of IL-3. Studies on the nervous systems of these two mouse lines are currently ongoing in our laboratory.
The pathology in the CNS lesions observed in these transgenic lines, with the exception of the mice reported by Chavany et al. (6) , is thought to be caused by glial or blood cells activated by overexpressed IL-3, although it has not been decided completely whether cytokines released from activated microglia and microglia themselves exert trophic or toxic effects on neurons (28, 35, 44, 46, 70) . However, the effects of overexpressed IL-3 on neurons are not serious (69) or not examined precisely (7, 9, 31, 54) except in the mice reported by Chavany et al. (6) . Septal cholinergic neurons especially have not been examined in all mouse lines. In the transgenic mice by Chavany et al. (6) , IL-3 seems to indirectly trigger the autoimmune reaction targeted to neurons. The findings observed in these transgenic mouse lines not only suggest the possibility of a toxic effect of IL-3 on neurons but also implicate the in vivo pharmacokinetics and especially toxicology of IL-3 exogenously administered to the nervous system and endogenously modified by manipulating the intracellular signal transduction system in target cells. 
CNS
THERAPEUTIC PROSPECTS OF IL-3 IN NEUROLOGIC DISORDERS
As mentioned in the introduction, most cytokines and their receptors have been identified in the nervous system and therefore have been thought to be involved with certain functions in the nervous system (24, 49, 63) . Now there are an increasing number of reports demonstrating that most cytokines play important roles in pathogenesis, not only in socalled immune-mediated neurologic disorders such as MS (53, 78) but also in neurodegenerative disorders such as Alzheimer's disease (45, 78) . This review article on the effects of IL-3 in the nervous system is expected to generate interest in both the close involvement of cytokines in neuropathogenesis and the promising prospects of cytokines as candidates for therapeutic strategies for modulating neuropathological conditions. Such promising and expanding prospects are not limited to a few cytokines (77) . Furthermore, Rothwell (62) mentioned the therapeutic potentials of cytokines for diverse neuropathological conditions. Recent studies on a variety of transgenic mouse lines have shown that overexpression of cytokines in the CNS can cause certain neurologic disorders (78) .
There are some discrepancies between the trophic or protective effects of IL-3 shown by numerous in vitro and in vivo studies and the results obtained from the transgenic mouse studies listed above. These discrepancies are not restricted to IL-3 but are common in most cytokines. The reasons for such discrepancies remain unclear. Most cytokines seem to have contradictory, bidirectional actions, beneficially trophic and unfavorably toxic to neurons (70, 78) . Such diverse actions should be considered in therapeutic strategies focusing on cytokines, thought to be due to the amounts and source (neuron-derived or glia-derived) of cytokines, the combinations with other cytokines, the conditions of cytokine targets and promoting cytokine production (steady or disease state), and especially the involvement of glia or blood cells activated by cytokines (indirect action on neurons). Discovery of the exact mechanisms that determine the directions of cytokine actions, either trophic or toxic, will yield a new strategy to regulate the clinical course and progression of neurologic disorders.
For example, a constitutively produced, neuron-derived small amount of IL-3 can exert direct trophic and protective effects on neurons. Conversely, an excess amount of IL-3 transiently released from glia under a stressed state can activate microglia to induce production of other toxic cytokines and expression of major histocompatibility complex Class II antigen (26) , resulting in enhancement of immunological reactions that can damage neuronal functions and viability, although microglia also have the possibility of interacting beneficially with neurons (28, 70) .
ADVERSE EFFECTS OF IL-3 ON THE NERVOUS SYSTEM
There is almost no information on pharmacology, pharmacokinetics, or adverse effects of IL-3 administered to the nervous system. Studies on transgenic mice reported by Chiang et al. (7), Chavany et al. (6) , D'Andrea et al. (9) , and Sugita et al. (69) can provide some information on adverse reactions when IL-3 levels are exogenously as well as en-dogenously increased in the nervous system. In trials of IL-3 therapy for hematological disorders, in addition, there are several reports regarding adverse effects (10) . Special attention should be focused on the adverse reactions observed in Phase I/Phase II clinical trials of IL-3 and IL-3/GM-CSF fusion protein for therapies of hematological and lymphoproliferative disorders (3, 11, 60) . Cockayne et al. (8) reported B-cell lymphoproliferative disorders occurring in transgenic mice expressing AS-IL-3 RNA. This is thought to be due to the chronic inhibition of IL-3 production from T cells. Both upregulation and downregulation of IL-3 signal (9) might cause hematolymphoproliferative disorders.
The key to solving the adverse effects may lie in the clarification of the mechanisms defining the action of IL-3 on inflammatory cells such as lymphocytes and macrophages/microglia, that have the possibility of exerting toxic influence on neurons. Cytokines may be manipulated to have toxic effects on neuronal functions once glial and immune cells are involved in the cytokine network, even if such cytokines have significant trophic effects directly on neurons in in vitro studies (73) . A variety of inflammation-related molecules, such as complement proteins, adhesion molecules and matrix proteins, can be involved in the in vivo cytokine network, especially in stressed and diseased conditions (32, 45, 62, 63, 78) .
CONCLUSIONS
IL-3 exerts direct, trophic or protective effects on some populations of neurons in both the central and peripheral nervous systems. IL-3 can rescue the axotomized cholinergic neurons and hippocampal CA1 neurons upon exposure to ischemia, as summarized in Table 3 . The studies on transgenic mice with overexpression of IL-3 or activation of its re-CNS Drug Reviews, Vol. 5, No. 3, 1999 
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Y. KONISHI ET AL. ceptors (Table 2) demonstrate that an excess amount of IL-3 can have indirect, unfavorable effects on neurons. There are some contradictions between the neurotrophic effects of IL-3 on neurons and the IL-3 actions in transgenic mouse lines. Like most cytokines, IL-3 has also contradictory, bidirectional actions, trophic and toxic to neurons. The mechanisms involved in each action have not been precisely elucidated as yet. Precise analyses of the mechanisms defining these diverse directions of IL-3 action, either beneficially trophic or unfavorably toxic to neurons, will certainly provide useful information concerning the delay or disruption of the progressive course of some neurologic disorders. The adverse effects of excess or deficient IL-3 signals in the brain remain unclear, but studies on transgenic and knockout mice may suggest the range and degree of adverse effects by IL-3 exogenously administered and endogenously manipulated in the brain.
